参考文献/References:
[1] Barbesino G, Tomer Y. Clinical review: clinical utility of TSH receptor antibodies[J].J Clin Endocrinol Metab,2013,98(6):2247-2255. DOI: 10.1210/jc.2012-4309.
[2] Lytton SD, Li Y, Olivo PD, et al. Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins[J].Clin Exp Immunol,2010,162(3):438-446. DOI: 10.1111/j.1365-2249.2010.04266.x.
[3] Jang SY, Shin DY, Lee EJ,et al. Relevance of TSH-receptor antibody levels in predicting disease course in Graves' orbitopathy: comparison of the third-generation TBII assay and Mc4-TSI bioassay[J].Eye(Lond),2013,27(8):964-971. DOI: 10.1038/eye.2013.120.
[4] Woo YJ, Jang SY, Lim TH, et al. Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves' orbitopathy[J].Korean J Ophthalmol,2015,29(4):213-219. DOI: 10.3341/kjo.2015.29.4.213.
[5] Hwang S, Shin DY, Song MK,et al. High cut-off value of a chimeric TSH receptor(Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months[J].Endocrine,2015,48(1):89-95. DOI: 10.1007/s12020-014-0325-8.
[6] Diana T, Li Y, Olivo PD,et al. Analytical performance and validation of a bioassay for thyroid-blocking antibodies[J]. Thyroid,2016,26(5):734-740. DOI: 10.1089/thy.2015.0447.
[7] Yamashita S, Amino N, Shong YK. The American Thyroid Association and American Association of Clinical Endocrinologists hyperthyroidism and other causes of thyrotoxicosis guidelines: viewpoints from Japan and Korea[J].Thyroid,2011,21(6):577-580. DOI: 10.1089/thy.2011.2106.ed1.
[8] Kahaly GJ, Bartalena L, Hegedüs L. The American Thyroid Association/American Association of Clinical Endocrinologists guidelines for hyperthyroidism and other causes of thyrotoxicosis: a European perspective[J].Thyroid,2011,21(6):585-591. DOI: 10.1089/thy.2011.2106.ed3.
[9] 曲莉,万晓艳,罗艳华. 促甲状腺激素受体抗体和甲状腺过氧化物酶抗体检测对Gravse病的诊断意义[J]. 中国地方病防治杂志,2013,28(6):429-430.
[10] 朱利国,浦洪波,武红玉,等. 促甲状腺激素、甲状腺过氧化物酶抗体和促甲状腺激素受体抗体检测在甲状腺疾病中的应用价值[J]. 标记免疫分析与临床,2010,17(4):241-243. DOI:10.3969/j.issn.1006-1703.2010.04.013.
[11] 伍宁玲,吕朝晖,杜锦,等. 促甲状腺激素受体抗体在Graves病中的诊断价值[J]. 解放军医学杂志,2011,36(5):501-504.
[12] 马萍. Graves病患者血清TRAb的检测及其临床意义[D].河北医科大学,2010.
[13] Cappelli C, Gandossi E, Castellano M,et al. Prognostic value of thyrotropin receptor antibodies(TRAb)in Graves' disease: a 120 months prospective study[J].Endocr J,2007,54(5):713-720.
[14] Chou KM, Huang BY, Chen CH, et al. Correlation and presentation of thyroid functional status with thyroid autoantibodies in long-term follow-up of autoimmune thyroiditis: a study of 116 cases[J].J Formos Med Assoc,2015,114(11):1039-1046. DOI: 10.1016/j.jfma.2013.05.017.
[15] Davies TF, Yeo PP, Evered DC, et al. Value of thyroid-stimulating-antibody determinations in predicting short-term thyrotoxic relapse in Graves' disease[J].Lancet,1977,1(8023):1181-1182.
[16] 宋武战,池君,汪静. 促甲状腺激素受体抗体(TRAb)测定的临床价值[J]. 放射免疫学杂志,2007,20(5):399-401. DOI:10.3969/j.issn.1008-9810.2007.05.007.
[17] Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor[J].Best Pract Res Clin Endocrinol Metab,2012,26(3):281-289. DOI: 10.1016/j.beem.2011.10.003.
[18] 程妍. 甲状腺相关眼病患者血清及泪液TPOAb、TRAb的检测及相关性分析[D].吉林大学,2014.
[19] Eckstein AK, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease[J].J Clin Endocrinol Metab,2006,91(9):3464-3470. DOI:10.1210/jc.2005-2813.
[20] 胡长军,张红,陆卫平. 甲减性心脏病患者血清促甲状腺激素受体抗体、抗甲状腺过氧化物酶抗体水平的变化[J]. 中国老年学杂志,2012,32(14):2938-2940.DOI:10.3969/j.issn.1005-9202.2012.14.014.
[21] Sugiura T, Yamanaka S, Takeuchi H, et al. Autoimmunity and pulmonary hypertension in patients with Graves' disease[J].Heart Vessels,2015,30(5):642-646. DOI: 10.1007/s00380-014-0518-3.
[22] 周静,王成蹊,侯连兵. 因宁片对甲亢性肝损害模型大鼠肝功能和氧化应激的影响[J]. 中药材,2011,34(2):278-281.
[23] 孟信龙. 新诊断Graves病患者肝功能异常的临床观察[J]. 临床医学,2013,33(9):73-74. DOI:10.3969/j.issn.1003-3548.2013.09.039.
[24] Li C, Tan J, Zhang G, et al. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study[J].Horm Metab Res,2015,47(3):209-213. DOI: 10.1055/s-0034-1375690.
[25] 李菊兰. 慢性HBV感染者血清甲状腺相关物质和IL-6的检测及其临床意义[D].福建医科大学,2014.
[26] Fatourechi V. Pretibial myxedema: pathophysiology and treatment options[J].Am J Clin Dermatol,2005,6(5):295-309.
[27] Takasu N, Higa H, Kinjou Y. Treatment of pretibial myxedema(PTM)with topical steroid ointment application with sealing cover(steroid occlusive dressing technique: steroid ODT)in Graves' patients[J]. Intern Med,2010,49(7):665-669.
[28] 赵志英,朱立,田健. 检测Graves病孕妇血清促甲状腺激素受体抗体的临床意义[J]. 生殖医学杂志,2010,19(4):318-321. DOI:10.3969/j.issn.1004-3845.2010.04.007.
[29] 赵志英,田健,朱立. 弥漫性毒性甲状腺肿病孕妇血清促甲状腺激素受体抗体水平对新生儿甲亢的影响[J]. 生殖医学杂志,2011,20(4):300-303. DOI:10.3969/j.issn.1004-3845.2011.04.012.
[30] Laurberg P, Bournaud C, Karmisholt J,et al. Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy[J].Eur J Endocrinol,2009,160(1):1-8. DOI: 10.1530/EJE-08-0663.
[31] Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum[J].Thyroid, 2011,21(10):1081-1125. DOI: 10.1089/thy.2011.0087.
相似文献/References:
[1]陈宁,朱云娟,陈慧,等.TSHR胞外区中间段在BALB/c小鼠体内的免疫原性研究[J].国际内分泌代谢杂志,2007,(04):267.
[2]朱丹,陈国芳,刘超,等.糖尿病患者合并甲状腺功能异常的机制
及其影响[J].国际内分泌代谢杂志,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
Zhu Dan*,Chen Guofang,Liu Chao,et al.Mechanisms of diabetes combined with thyroid dysfunction and its influence[J].International Journal of Endocrinology and Metabolism,2016,36(02):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
[3]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的
相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(02):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[4]刘燕晶 张帆.甲状腺功能亢进症性肝损害的发生机制[J].国际内分泌代谢杂志,2019,39(01):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
Liu Yanjing,Zhang Fan.The pathogenesis of liver damage of hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2019,39(02):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
[5]姚瑶,郑仁东,刘超.血浆置换治疗甲状腺功能亢进症的研究进展[J].国际内分泌代谢杂志,2020,40(05):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
Yao Yao,Zheng Rendong,Liu Chao.Update on plasmapheresis for hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2020,40(02):320.[doi:10.3760/cma.j.cn121383-20191218-12047]
[6]朱航毅,赵一璟,史雨清,等.碳酸锂致肾性尿崩症的研究进展[J].国际内分泌代谢杂志,2022,42(06):485.[doi:10.3760/cma.j.cn121383-20210530-05078]
Zhu Hangyi,Zhao Yijing,Shi Yuqing,et al.Research progress of nephrogenic diabetes insipidus induced by carbonate lithium[J].International Journal of Endocrinology and Metabolism,2022,42(02):485.[doi:10.3760/cma.j.cn121383-20210530-05078]
[7]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(02):5.[doi:10.3760/cma.j.cn121383-20200608-06021]